Deutsche Bank has a rating of Hold on the stock and a $26 price target. The consensus target is higher at $27.09. Shares closed trading at $25.13. Medivation Inc. (NASDAQ: MDVN) is a stock many Wall Street analysts are very bullish on. …
A California Superior Court judge has ruled against Medivation, Inc. (NASDAQ:MDVN) in the case of Medivation ... and is likely to become a blockbuster drug as many expect and the stock price indicates. However, ARN-509's potential …
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only ... At Medivation ( MDVN), a filing with the SEC revealed that on Friday, …
MDVN’s niche is research into other diseases for which few treatment options exist, but none of this new research is close enough to warrant owning the stock at $129 a share. Well, yipsee doodle dandy, I like your selection of Universal …
They are Medivation (NASDAQ: MDVN), Synageva BioPharma (NASDAQ ... Its market capitalization is near $4.0 billion and the stock jumped to a new multiyear high last week following news that the company won approval from the FDA …
Medivation (NASDAQ:MDVN) is a large capitalization ($10 billion ... These results have driven the stock price from a $54.47 in April, 2014 to a 52-week high of $141.48 on March 23, 2015. Clearly Medivation beat the iShares …
MDVN). Pfizer now expects to complete the acquisition in the Third-Quarter 2016. The closing of the tender offer remains subject to other customary closing conditions, including the tender of a majority of the outstanding shares of Medivation …
The stock was trading at $20.19 at Friday’s closing bell ... CRR), Medivation Inc. (NASDAQ: MDVN) and Mondelez International Inc. (NASDAQ: MDLZ). Many of the companies mentioned are seeing return buyers. That is a solid sign …
Medivation Inc (NASDAQ: MDVN) reported its U.S. and ex-U.S. Xtandi sales for 1Q16 ... Aschoff believes take-out speculations could continue to drive the stock, “along with the growing Xtandi sales and clinical and regulatory …